KnowBe4 Announces New Assessment Tool to Enable Data-Driven Security Culture Improvements
As human actions are targeted and exploited by attackers with increased sophistication, organizations need clarity on what is working and how to measure improvement. According to KnowBe4's Security Culture: How-To Guide, security culture is one of the strongest predictors of secure behavior, yet few organizations have the tools to assess and manage it effectively.
Created by security culture expert Perry Carpenter, the PMA offers a structured, practical self-assessment framework focused on Human Risk Management (HRM). Unlike technical assessments or consultant-heavy frameworks, the PMA delivers actionable insights across ten critical dimensions of security culture—without the jargon. It translates abstract cybersecurity concepts into concrete actions that organizations can take immediately, regardless of size or industry.
Key Features of the PMA:
After completing the assessment, users receive a personalized maturity classification on a five-level scale, visual feedback across all dimensions, and prioritized recommendations. Those looking to deepen their efforts can opt into a follow-up consultation to explore how the KnowBe4 HRM+ platform can accelerate maturity and build a lasting security culture.
'Every meaningful program requires clarity: clarity of purpose and clarity of impact. This is especially true with Human Risk Management programs where lack of clarity and impact will leave an organization exposed in ways they may not appreciate.' said Perry Carpenter, chief human risk management strategist at KnowBe4. 'Organizations need a way to demonstrate effectiveness of their human risk management program and show leadership its value. This is especially true when programs fail to account for the human element—employees whose everyday decisions significantly impact organizational security. The PMA offers a clear, data-driven approach that helps leaders identify key areas for improvement, allocate resources more effectively, and build a stronger, more resilient security culture. It's about giving organizations the insight they need to make informed decisions and foster lasting cultural change.'
To learn more or complete the assessment, visit www.KnowBe4.com
About KnowBe4
KnowBe4 empowers workforces to make smarter security decisions every day. Trusted by over 70,000 organisations worldwide, KnowBe4 helps to strengthen security culture and manage human risk. KnowBe4 offers a comprehensive AI-driven 'best-of-suite' platform for Human Risk Management, creating an adaptive defense layer that fortifies user behavior against the latest cybersecurity threats. The HRM+ platform includes modules for awareness & compliance training, cloud email security, real-time coaching, crowdsourced anti-phishing, AI Defense Agents, and more. As the only global security platform of its kind, KnowBe4 utilises personalised and relevant cybersecurity protection content, tools and techniques to mobilise workforces to transform from the largest attack surface to an organisation's biggest asset.
Kathy Wattman KnowBe4, Inc. 7274749950 [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
BTCMiner Redefines Crypto Investment with Safe, Efficient Cloud Mining Solutions
Coinbase, a leading cryptocurrency exchange, has seen its stock price soar to its highest level since its Nasdaq listing, reflecting growing investor confidence in the cryptocurrency sector. Amid this milestone, industry leaders are emphasizing the transformative potential of cryptocurrency cloud mining as a cornerstone of the investment landscape. A senior executive at Coinbase recently highlighted the critical role of cloud mining in addressing global economic challenges, stating, 'In an era of escalating global debt, persistent inflation, and diminishing economic freedom, cryptocurrency cloud mining offers a pathway to expand financial sovereignty and empower investors worldwide.' This perspective was first highlighted in a press release published by GlobeNewswire: BTCMiner: Ten Years of Safe and Stable Cloud Mining, Principal and Interest Guaranteed. The executive's remarks, shared on the BTCMiner platform, underscore the rising prominence of cloud mining as a low-barrier, high-potential investment avenue. As the cryptocurrency market evolves, platforms like BTCMiner are leading the charge by offering secure, efficient, and user-friendly solutions for investors seeking to capitalize on this innovative technology. BTCMiner: A Leader in Cryptocurrency Cloud Mining BTCMiner has emerged as one of the safest and most reliable cloud mining platforms in the industry, distinguished by its commitment to transparency, security, and efficiency. The platform offers a range of unique features designed to provide investors with peace of mind and consistent returns: Welcome Bonus: New users receive a $500 trial contract upon registration, enabling them to explore the platform's capabilities risk-free. This contract can be activated daily, offering a low-risk entry point for new investors. Regulatory Oversight: BTCMiner operates under the supervision of the UK's Financial Conduct Authority (FCA), ensuring regular audits and adherence to stringent regulatory standards. Principal and Interest Guarantee: The platform's innovative contract structure locks in both principal and returns, safeguarding investors against market volatility and ensuring predictable income. Energy Efficiency: BTCMiner employs an intelligent scheduling system that optimizes computing resources in real time, minimizing energy waste and enhancing mining efficiency. 'Cloud mining democratizes access to cryptocurrency investment,' said a prominent industry analyst. 'Platforms like BTCMiner are redefining the sector by combining cutting-edge technology with investor-focused features, making it easier than ever for individuals to participate in the crypto economy.' How to Get Started with BTCMiner Joining BTCMiner is a seamless process designed for accessibility and convenience: Create an Account: Visit the official website at provide an email address, and set a secure password to register. Claim Your Trial Contract: Upon successful registration, users instantly receive a $500 trial contract, which can be activated daily to generate returns. Select and Activate Contracts: Choose from a range of mining contracts, place an order with a single click, and monitor earnings in real time. Profits are automatically settled every 24 hours, ensuring transparency and ease of use. Explore additional contract options at to tailor your investment strategy Lucrative Referral Program BTCMiner also offers an attractive invitation rewards program, enabling users to earn passive income by sharing their exclusive referral links on social media. The program features a tiered reward structure: Level 1: Earn a 7% commission on the investments of directly referred users. Level 2: Receive a 2% commission on the investments of users referred by your direct referrals. Payments are processed in real time, providing an opportunity for users to generate additional income effortlessly. The Future of Cloud Mining Cloud mining represents a paradigm shift in cryptocurrency investment, characterized by its low entry threshold, cost-effectiveness, and automated management. By eliminating the need for expensive hardware or technical expertise, platforms like BTCMiner are making cryptocurrency mining accessible to a global audience. Looking ahead, BTCMiner is committed to further optimizing its resource allocation algorithms and enhancing mining efficiency to deliver even greater value to its users. As the cryptocurrency market continues to mature, cloud mining is poised to play a pivotal role in shaping the future of digital finance. With its robust features, regulatory compliance, and user-centric approach, BTCMiner is well-positioned to lead this transformation. Join the Cloud Mining Revolution Investors seeking to capitalize on the growing cryptocurrency market are encouraged to explore BTCMiner's offerings. New users can register today at to claim their $500 trial contract and begin their cloud mining journey. For additional information, contact BTCMiner's support team at info@ About BTCMiner BTCMiner is a leading cloud mining platform dedicated to providing secure, efficient, and accessible cryptocurrency mining solutions. With a focus on innovation and user satisfaction, BTCMiner is empowering investors to participate in the global cryptocurrency economy. Click here to download the BTCMiner platform APP Disclaimer The information provided in this press release does not constitute investment advice. Cryptocurrency investments carry inherent risks, and past performance is not indicative of future results. Users are advised. One project frequently cited in this context is BTCMiner, a platform that recently marked its tenth year in operation. Its longevity and stable performance were covered in a GlobeNewswire article, which highlighted BTCMiner's track record of delivering safe and consistent cloud mining services with a principal and interest guarantee.
Business Upturn
3 hours ago
- Business Upturn
GRANDE GROUP LIMITED ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING
Hong Kong, July 02, 2025 (GLOBE NEWSWIRE) — GRANDE GROUP LIMITED ('GRAN' or the 'Company'), a Hong Kong-based financial services provider which principally engages in the provision of corporate finance advisory services and IPO sponsor services through its Hong Kong subsidiary, Grande Capital Limited, today announced the closing of its initial public offering (the 'Offering') of 1,875,000 Class A ordinary shares (the 'Class A Ordinary Shares') at the price of $5.00 per share (the 'Offering Price'). The Class A Ordinary Shares commenced trading on the Nasdaq Capital Market on July 1, 2025, under the ticker symbol 'GRAN.' The Company received gross proceeds of approximately US$9.375 million from the Offering, before deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 281,250 Class A Ordinary Shares of the Company at the Offering Price, representing 15% of the Class A Ordinary Shares sold in the Offering (the 'Over-Allotment Options'). The Company intends to use the net proceeds from the Offering for strengthening the corporate finance advisory business, developing the asset management business, establishing equity capital market services, and general working capital purposes. The Offering was conducted on a firm commitment basis. Cathay Securities, Inc. acts as the underwriter (the 'Underwriter') for the Offering. Ortoli Rosenstadt LLP acts as the U.S. securities counsel to the Company. Ogier acts as the British Virgin Islands legal counsel to the Company. Loong & Yeung and David Fong & Co. act as the Hong Kong legal counsels to the Company. WWC, P.C. acts as the independent registered public accounting firm of the Company. Hunter Taubman Fischer & Li LLC acts the U.S. securities counsel to the Underwriter, in connection with the Offering. The Offering was conducted pursuant to the Company's Registration Statement on Form F-1 (File No. 333-283705) previously filed with, and subsequently declared effective on June 30, 2025 by the U.S. Securities and Exchange Commission (the 'SEC'). A final prospectus describing the terms of the Offering was filed with the SEC on July 1, 2025 and is available on the SEC's website at Alternatively, the copies of the final prospectus related to the Offering may be obtained, when available, from Cathay Securities, Inc.: 40 Wall St Suite 3600, New York, NY 10005, United States, Attention: Shell Li, or via email at [email protected] or telephone at +1 (855) 939-3888. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Grande Group Limited Through its Hong Kong subsidiary, Grande Capital Limited, Grande Group Limited is a Hong Kong-based financial services provider which principally engages in the provision of corporate finance advisory services and IPO sponsor services. Grande Capital Limited is licensed with the Securities and Futures Commission of Hong Kong ('HKSFC') to engage in Type 1 (dealing in securities) and Type 6 (advising on corporate finance) regulated activities in Hong Kong. For more information, please visit: Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding its intended use of proceeds from the sale of the Company's Class A Ordinary Shares in the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion of the initial public offering on the anticipated terms or at all, and other factors discussed in the 'Risk Factors' section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: Grande Group Limited Investor Relations Contact:Christensen AdvisoryJoanna Quan Email:[email protected] Tel: +86-10-5900-1548
Business Upturn
3 hours ago
- Business Upturn
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8 th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects — especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register (here) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in (here) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers 17 advanced metastatic gastric cancer patients were treated with givastomig across the 5 mg/kg (n=5), 8 mg/kg (n=6), and 12 mg/kg (n=6) dose levels as of the May 15, 2025 data cutoff. All patients were efficacy evaluable Patient Characteristics: The 17 patients enrolled in the study were treatment naïve metastatic gastric, esophageal or gastroesophageal adenocarcinomas Patients were HER2-negative, Claudin 18.2-positive (defined as ≥1+ IHC staining intensity in ≥1% of tumor cells), regardless of PD-L1 expression levels All patients were enrolled at sites within the United States Efficacy Results: Confirmed Objective Response Rates (ORRs): 71% of patients (12/17) achieved a partial response (PR) per RECIST v1.1 5 mg/kg (2/5) 8 mg/kg (5/6) 12 mg/kg (5/6) At the doses selected for dose expansion (8 and 12 mg/kg), 83% (10/12) of patients achieved PRs 80% of patients (4/5) with CLDN18.2 expression below 75% (CLDN-Low) achieved a PR. The CLDN-Low response rate increased to 100% of patients (3/3) in the doses selected for expansion (8 and 12 mg/kg) The disease control rate (DCR) was 100% across the three dose levels Dose-dependent pharmacokinetics (PK) were observed, similar to monotherapy PK Patients also experienced a dose dependent induction of soluble 4-1BB, a positive indicator of T cell activation and engagement ORR: % (n) All (n=17) Cohorts Chosen for Expansion (8 and 12 mg/kg) (n=12) PD-L1 Any 71 (12/17) 83 (10/12) ≥5 82 (9/11) 89 (8/9) <5 50 (3/6) 67 (2/3) ≥1 73 (11/15) 82 (9/11) <1 50 (1/2) 100 (1/1) CLDN18.2 ≥75 67 (8/12) 78 (7/9) <75 80 (4/5) 100 (3/3) ORR: % (n) PD-L1 ≥ 5 PD-L1 < 5 CLDN18.2 ≥ 75 80 (8/10) 0 (0/2) CLDN18.2 < 75 100 (1/1) 75 (3/4) Durability: 8 of 17 patients remained on study treatment and the longest treatment duration was 13.3 months as of the data cutoff Median follow-up was 9.0 months across all dose levels as of the data cutoff Safety: Treatment-related adverse events (TRAEs) leading to discontinuation of any treatment were 12% (two patients), five patients had progressive disease, two patients withdrew from the study for social reasons No dose limiting toxicities (DLT) were observed and a maximum tolerated dose (MTD) was not reached Common TRAEs (≥10% of patients) were generally Grade 1 or Grade 2 including nausea, vomiting, infusion related reaction, fatigue, decreased appetite, diarrhea, abdominal pain, chills, dyspepsia and gastritis Grade 3 TRAEs attributed to givastomig were rare, with single cases of abdominal pain, ALT/AST increases, gastritis, and infusion related reaction Four cases of Grade 3 and two cases of Grade 4 treatment-related neutropenia were observed driven by an early restriction on prophylaxis use of G-CSF, which has been subsequently lifted. The neutropenia cases were primarily attributed to mFOLFOX6 in the 8 mg/kg cohorts No Grade 5 TRAEs were reported About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media ContactsPJ KelleherLifeSci Advisors+1-617-430-7579 [email protected] [email protected]
